AU2720388A - New therapeutical use of h2-receptor-blocking compounds - Google Patents

New therapeutical use of h2-receptor-blocking compounds

Info

Publication number
AU2720388A
AU2720388A AU27203/88A AU2720388A AU2720388A AU 2720388 A AU2720388 A AU 2720388A AU 27203/88 A AU27203/88 A AU 27203/88A AU 2720388 A AU2720388 A AU 2720388A AU 2720388 A AU2720388 A AU 2720388A
Authority
AU
Australia
Prior art keywords
receptor
blocking compounds
therapeutical use
new therapeutical
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU27203/88A
Inventor
Rolf Hakanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassle AB filed Critical Hassle AB
Publication of AU2720388A publication Critical patent/AU2720388A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
AU27203/88A 1987-11-13 1988-10-27 New therapeutical use of h2-receptor-blocking compounds Withdrawn AU2720388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704436A SE8704436D0 (en) 1987-11-13 1987-11-13 USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS
SE8704436 1987-11-13

Publications (1)

Publication Number Publication Date
AU2720388A true AU2720388A (en) 1989-06-01

Family

ID=20370204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27203/88A Withdrawn AU2720388A (en) 1987-11-13 1988-10-27 New therapeutical use of h2-receptor-blocking compounds

Country Status (7)

Country Link
EP (1) EP0353262A1 (en)
JP (1) JPH02502188A (en)
AU (1) AU2720388A (en)
DK (1) DK329289D0 (en)
HU (1) HUT51894A (en)
SE (1) SE8704436D0 (en)
WO (1) WO1989004178A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607451B2 (en) * 1986-12-12 1991-03-07 Glaxo Group Limited Pharmaceutical compositions

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
KR20030097611A (en) * 1997-07-22 2003-12-31 머크 앤드 캄파니 인코포레이티드 Composition for inhibiting bone resorption
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
DK3021832T3 (en) 2013-07-19 2021-05-25 Boehringer Ingelheim Vetmedica Gmbh PRESERVED ETHERIFIED CYCLODEXTRINE DERIVATIVES CONTAINING LIQUID AQUATIC PHARMACEUTICAL COMPOSITION
EA201992230A1 (en) 2013-12-04 2020-02-28 Бёрингер Ингельхайм Ветмедика Гмбх IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4220653A (en) * 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4256743A (en) * 1979-02-22 1981-03-17 President And Fellows Of Harvard College Inhibition of bone resorption with H1 -blocking antihistamines
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607451B2 (en) * 1986-12-12 1991-03-07 Glaxo Group Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
DK329289A (en) 1989-07-03
WO1989004178A1 (en) 1989-05-18
HU886797D0 (en) 1990-05-28
SE8704436D0 (en) 1987-11-13
DK329289D0 (en) 1989-07-03
JPH02502188A (en) 1990-07-19
EP0353262A1 (en) 1990-02-07
HUT51894A (en) 1990-06-28

Similar Documents

Publication Publication Date Title
AU1676588A (en) Treatment of materials
GB2231265B (en) Therapeutic use of serotonin-antagonists
AU4285889A (en) Preparation of catheter
GB8719367D0 (en) Therapeutic compounds
JPS6471896A (en) Manufacture of alkyloligoglycoside
JPS6471895A (en) Manufacture of alkyloligoglycoside
JPS6471897A (en) Manufacture of alkyloligoglycoside
ZA884464B (en) Use of olefinic compounds
AU2297388A (en) Therapeutic agents
AU1309188A (en) New compounds
AU2720388A (en) New therapeutical use of h2-receptor-blocking compounds
AU629002B2 (en) Preparation of tertiary-hydrocarbylsilyl compounds
GB8725939D0 (en) Therapeutic compounds
AU1767688A (en) Use of dioxopiperidine derivatives as analgesics
JPS6450830A (en) Manufacture of polyfluorobutene
GB8725334D0 (en) Preparation of benzothiazole-2-sulphenamides
JPS6450842A (en) Manufacture of alkylpentenoate
EP0295361A3 (en) Preparation of pseudoionones
AU1148888A (en) New compounds
AU2075388A (en) Novel synthesis of 3-amino-2-methylbenzotrifluoride
AU7481287A (en) Therapeutic use of tin diiododeuteroporphyrin
GB2217729B (en) Obtenation of scualane
AU2491388A (en) 4h-quinolizin-4-one compounds exhibiting therapeutic activities
IL85656A0 (en) Preparation of phenylacetaldehydes
AU2564688A (en) Treatment of fibromyalgia